As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

Expert Dr. Salas-Whalen reveals that body composition testing, not just the number on your scale, is key to knowing whether ...

GLP-1 drugs, originally for type 2 diabetes, are increasingly used for weight loss, but they can worsen eating disorders. Rapid weight loss from these drugs can reinforce harmful eating behaviors and ...

Saha is senior vice president of government affairs for Premier Inc. McMullan is senior director of payment policy at Premier Inc. Today, more than 40% of adults over 60 are considered obese, fueling ...

One in eight Americans is currently taking a GLP-1 to lose weight or treat a chronic condition.

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending for the first time, according to a March 25 report from Evernorth. The ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. The U.S. Food and Drug Administration (FDA) recently ...

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the risk of serious kidney injury that can result from dehydration. This comes ...

Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery ...

Researchers are studying whether these widely used weight-loss drugs may also be future treatments for alcohol abuse.

GLP-1 weight loss drugs are proving beneficial for people struggling with obesity and diabetes, but there is another surprising side effect coming to light.

The MarketWatch News Department was not involved in the creation of this content. Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like ...